Tamoxifen 20mg Tablets

Description

Tamoxifen doesn’t reduce estrogen in the body — it selectively blocks estrogen from reaching its receptors in breast tissue. That distinction matters, and it’s what makes tamoxifen fundamentally different from aromatase inhibitors like anastrozole. Where anastrozole cuts estrogen production across the body, tamoxifen works at the receptor level, occupying estrogen receptors in breast cells before estrogen can bind to them and trigger growth.

The result is targeted anti-estrogenic action in breast tissue — without eliminating estrogen from the body entirely.

The SERM Mechanism — Selective by Design

Tamoxifen is a selective estrogen receptor modulator (SERM) — and the “selective” part is the key. It behaves differently in different tissues. In breast tissue it acts as an estrogen antagonist, blocking the receptor and preventing estrogen from stimulating cancer cell growth. In bone tissue it acts as an estrogen agonist — mimicking estrogen’s bone-protective effect, which helps preserve bone density during long-term treatment. In the uterus it has mild estrogenic activity, which is the basis for its main serious side effect.

This tissue selectivity is what allows tamoxifen to do its job in the breast without stripping estrogen protection from every system in the body — a meaningful practical advantage, particularly for premenopausal women who still need estrogen for bone, cardiovascular, and general health.

Where It’s Used

Hormone receptor-positive breast cancer is the primary indication — tumours that express estrogen receptors (ER-positive) and use estrogen to drive their growth. Tamoxifen is effective for both premenopausal and postmenopausal women, which is where it differs from aromatase inhibitors that only work in postmenopausal patients. Adjuvant treatment after surgery — typically five to ten years — reduces recurrence risk by around 30 to 50% in premenopausal patients and a similar range in postmenopausal patients. It’s also used to lower breast cancer risk in high-risk individuals who haven’t yet developed the disease.

In men, tamoxifen is used for hormone receptor-positive male breast cancer and off-label for gynecomastia — excess breast tissue development — where blocking estrogen receptors in breast tissue directly addresses the underlying driver.

Tamoxifen vs Anastrozole — Which One

Both are used in hormone receptor-positive breast cancer, but they’re not interchangeable. Tamoxifen blocks estrogen receptors. Anastrozole (an aromatase inhibitor) reduces estrogen production. For premenopausal women, tamoxifen is the standard choice — aromatase inhibitors are largely ineffective before menopause because the ovaries continue producing estrogen regardless. For postmenopausal women, both are options and the decision depends on individual clinical factors. The two are sometimes used sequentially — tamoxifen first, transitioning to an aromatase inhibitor after menopause.

20mg — The Standard Daily Dose

A single 20mg tablet daily is the established clinical dose for breast cancer treatment and prevention. Long-term use — five to ten years — is the norm for adjuvant treatment rather than a short course.

No Prescription. Worldwide Delivery.

Ordered directly, dispatched fast in completely plain unmarked packaging. No prescription required, tracked to your door anywhere in the world.

Tamoxifen increases the risk of uterine cancer, blood clots, and stroke with long-term use — these risks should be weighed against the benefits, which are substantial for ER-positive breast cancer. Do not take during pregnancy — use non-hormonal contraception while taking it and for two months after stopping. Avoid grapefruit. Strong CYP2D6 inhibitors including paroxetine significantly reduce tamoxifen’s effectiveness.